Kalvista Pharmaceuticals Inc

NASDAQ KALV

Data sourced from

and

Download Data

Kalvista Pharmaceuticals Inc Net Operating Profit After Tax (NOPAT) 5 year CAGR for the quarter ending October 31, 2023: 60.71%

Kalvista Pharmaceuticals Inc Net Operating Profit After Tax (NOPAT) 5 year CAGR is 60.71% for the quarter ending October 31, 2023, a 93.74% change year over year. Net Operating Profit After Taxes (NOPAT) is a financial metric that represents a company's operating profit after deducting taxes. It is calculated by multiplying the earnings before interest and taxes (EBIT) by (1 - tax rate). NOPAT provides insights into the company's profitability from its core operations while accounting for the impact of taxes. It is useful for assessing the company's operating performance and comparing profitability across different tax environments. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Kalvista Pharmaceuticals Inc Net Operating Profit After Tax (NOPAT) for the quarter ending January 31, 2023 was -18,529,406.37, a 13.10% change year over year.
Kalvista Pharmaceuticals Inc Net Operating Profit After Tax (NOPAT) for the quarter ending January 31, 2022 was -21,323,638.05, a -138.68% change year over year.
Kalvista Pharmaceuticals Inc Net Operating Profit After Tax (NOPAT) for the quarter ending January 31, 2021 was -8,933,799.96, a -23.35% change year over year.
Kalvista Pharmaceuticals Inc Net Operating Profit After Tax (NOPAT) for the quarter ending January 31, 2020 was -7,242,910.77, a -319.38% change year over year.

NASDAQ: KALV

Kalvista Pharmaceuticals Inc

CEO	Mr. Thomas Andrew Crockett M.B.A.
IPO Date	April 9, 2015
Location	United States
Headquarters	55 Cambridge Parkway, Cambridge, MA, United States, 02142
Employees	118
Sector	Healthcare
Industry	Biotechnology

Description

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.

Key trends